17:29 , Sep 28, 2018 |  BC Week In Review  |  Clinical News

Innovent's PD-1 Inhibitor leads to 22.7% ORR in Phase Ib for NETs

Innovent Biologics Inc. (Suzhou, China) said anti-PD-1 antibody sintilimab (IBI308) led to an objective response rate (ORR) of 22.7% in 22 evaluable patients with neuroendocrine tumors (NETs) who failed standard therapy in a Chinese Phase...
21:57 , Sep 21, 2018 |  BC Extra  |  Clinical News

Innovent reports Chinese NET, NSCLC data for PD-1 mAb

Innovent Biologics Inc. (Suzhou, China) presented data this week from neuroendocrine tumor and non-small cell lung cancer cohorts in its Chinese Phase Ib trial of anti-PD-1 mAb sintilimab (IBI308). Data were presented at the Chinese...
18:21 , Aug 31, 2018 |  BC Week In Review  |  Financial News

Harbour BioMed raises $85M series B on heels of cancer deals

Immuno-oncology company Harbour BioMed (Shanghai, China) raised $85 million in a series B round led by GIC. New investors China Life Private Equity Investment Company and Vertex Ventures also participated as did existing investors AdvanTech...
18:20 , Aug 31, 2018 |  BC Week In Review  |  Company News

Harbour gets ex-China rights to Kelun's anti-PD-L1 mAb

Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. granted Harbour BioMed (Shanghai, China) exclusive rights to anti-PD-L1 antibody A167 outside of the Greater China region. Kelun-Biotech is the small molecules and biologics-focused subsidiary of Sichuan Kelun Pharmaceutical Co....
19:02 , Aug 30, 2018 |  BioCentury  |  Finance

Building a deeper Harbour

With an $85 million B round in hand, Harbour BioMed plans to advance newly in-licensed clinical programs while simultaneously building its pipeline through its internal platform and co-discovery deals. Singapore sovereign wealth fund GIC led...
22:31 , Aug 27, 2018 |  BC Extra  |  Financial News

Harbour BioMed raises $85M on heels of cancer deals

Immuno-oncology company Harbour BioMed (Shanghai, China) raised $85 million in a series B round led by GIC. New investors China Life Private Equity Investment Company and Vertex Ventures also participated as did existing investors AdvanTech...
21:12 , Aug 20, 2018 |  BC Extra  |  Company News

Harbour gets ex-China rights to Kelun's anti-PD-L1 mAb

Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. granted Harbour BioMed (Shanghai, China) exclusive rights to anti-PD-L1 antibody A167 outside of the Greater China region. Kelun-Biotech is the small molecules and biologics-focused subsidiary of Sichuan Kelun Pharmaceutical Co....